StemRIM Announces Completion of Patient Enrollment in the Phase 1,2 Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy4/15 15:30TDnetPDF(171KB)
Presentation Material Financial Results for the Six Months Ended January 31, 20263/13 16:0TDnetPDF(3MB)
Non-consolidated Financial Results for the Six Months Ended January 31, 2026 [Japanese GAAP]3/11 15:30TDnetPDF(442KB)
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code: SR-GT1) Aimed at Curative Treatment of DEB3/2 15:30TDnetPDF(288KB)
StemRIM Announces Patent Registration (Canada) for the Use of Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders2/17 15:30TDnetPDF(169KB)
StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke2025/12/25TDnetPDF(155KB)
StemRIM Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty L2025/12/17TDnetPDF(150KB)
Non-consolidated Financial Results for the Three Months Ended October 31, 2025 [Japanese GAAP]2025/12/10TDnetPDF(309KB)
StemRIM Announces the Formation of a Compensation Committee on a Voluntary Basis2025/12/10TDnetPDF(141KB)
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation2025/12/10TDnetPDF(145KB)
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock2025/11/12TDnetPDF(181KB)